

CONTENTS

Title	Page No.
List of abbreviations	I
List of tables	III
List of figures	IV
Introduction	1
Aim of the work	3
Acute poststreptococcal glomerulonephritis	4
1-1 Introduction	4
1-2 Epidemiology	6
1-3 Pathogenesis	7
1.3.1 Streptococcal Antigens and Immune Reactivity	7
1.3.2 Autoimmune Reactivity	10
1.3.3 Cytokines and Chemokines	11
1.4 Clinical Characteristics	12
1.5 Pathophysiology of the Acute Nephritic Syndrome	14
1.6 Serological Findings	15
1.6.1 Complement changes.	15
1.6.2 Anti-zSPEB/SPEB	16
1.6.3 Antistreptolysin O titers and anti-DNAse.	16
1.7 Pathology	16
1.7.1 Indications of renal biopsy	16
1.7.2 Biopsy findings in APSGN	17
1.8 Diagnosis	18
1.9 Treatment	20
1.9.1 Antibiotics	20
1.9.2 Diuretics	22
1.9.3 Antihypertensives	22
1.10 Prognosis of APSGN	23
Lupus nephritis	25
1.1 Introduction	25
1.2 Pathogenesis of LN	28
1.3 Clinical Findings	30

Title	Page No.
1.3.1 History	30
1.3.2 Physical examination:	31
1.4 Histologic Classification	31
1.4.1 Class I	36
1.4.2 Class II	36
1.4.3 Class III	37
1.4.4 Class IV	37
1.4.5 Class V	38
1.4.6 Class VI	39
1.5 Activity and Chronicity Indices	39
1.6 Prognostic Factors in Patients with LN	41
1.7 Laboratory Investigations	44
1.7.1 Anti-DNA antibodies	44
1.7.2 Antinuclear antibodies (ANA)	45
1.7.3 Anti-Sm antibodies	45
1.7.4 Antiribonucleoprotein antibodies	45
1.7.5 Antierythrocyte, Antiplatelet and Antilymphocyte Ab	45
1.7.6 Anti-C1q antibodies	45
1.7.7 Antiphospholipid (APL) antibodies	46
1.7.8 Hypocomplementemia	46
1.8 Treatment of LN	46
1.8.1 Therapy of Patients with Mild Renal Lesions	46
1.8.2 Therapy of Patients with Class III LN	47
1.8.3 Therapy of Patients with Class IV LN	47
1.8.4 Induction therapy	47
Pulse Methylprednisolone	47
Cyclophosphamide: High-dose vs. Low-dose	48
Azathioprine	50
Mycophenolate Mofetil	50
Plasma exchanges	51
1.8.5 Maintenance Therapy	52
1.8.6 Treatment of Relapses	53

Title	Page No.
1.8.7 Other Therapeutic Approaches	53
Rituximab	53
IV Igs	54
LJP-394	54
Anti-CD 40	55
CTLA 4 Ig	55
1.9 Prognosis and Complications	55
1.9.1 Infectious complications	55
1.9.2 Accelerated atherosclerosis	56
1.9.3 Myocardial infarction	56
1.9.4 Thrombosis	56
1.9.5 End stage renal failure	57
1.9.6 Corticosteroids complications	57
1.9.7 Cytotoxic drugs complications	58
Complement	59
1.1 Introduction	59
1.2 Role of anti-C1q in the development of glomerular injury and ANA	62
1.3 Pathogenisity of anti-C1q	62
1.4 Anti-C1q increase the complement activation in a relatively uncontrolled fashion	63
1.5 Mechanism of activation of classical and alternative pathways and generation of C3 convertases	64
1.6 The role of anti-C1q in glomerulonephritis	65
1.7 Additional deleterious roles potentially played by anti-C1q	65
Subjects and methods	67
Results	78
Discussion	99
Summary and conclusion	106
Recommendations	112
References	113
Arabic summary	